x

Search for a clinical trial

* (*) mandatory field

115 Result(s)

Sort by

Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial
; Funded by an IRDiRC member =

National clinical trial(s)

FRANCE

NOUVELLE AQUITAINE
POITIERS

FRANCE

NOUVELLE AQUITAINE
POITIERS

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

GERMANY

Baden-Württemberg
TÜBINGEN

Phase I/II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts in patients with treatment refractory hematologic malignancies - DE
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

GERMANY

Berlin
BERLIN

ENEST1st: A Phase IIIb, multicentre, open-label study of Nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase - DE - Completed
Charité - Universitätsmedizin Berlin (CVK)
Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie

GERMANY

Berlin
BERLIN

Ongoing trial
ENESTop: A Phase II, single arm, open label study of treatment-free remission in Chronic Myeloid Leukemia chronic phase patients after achieving sustained MR4.5 on Nilotinib - DE
Charité - Universitätsmedizin Berlin (CVK)
Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie

GERMANY

Nordrhein-Westfalen
AACHEN

Ongoing trial
A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia - DE
Universitätsklinikum Aachen
Klinik für Onkologie, Hämatologie und Stammzelltransplantation (Med. Klinik IV)

GERMANY

Nordrhein-Westfalen
ESSEN

GERMANY

Sachsen
DRESDEN

GERMANY

Thüringen
JENA

An open label phase II study of the combination of Imatinib and Lonafarnib in patients with CML in chronic phase and absence of good molecular remission - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

GERMANY

Thüringen
JENA

Ongoing trial
PACE (AP24534-10-201) : A pivotal phase 2 trial of ponatinib (AP24534) in patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

GERMANY

Thüringen
JENA

GERMANY

Thüringen
JENA

ITALY

EMILIA ROMAGNA
BOLOGNA

Recruiting trial
Ongoing trial
Dasatinib (BMS-354825) combined with SMO inhibitor (BMS-833923; XL139) in CML with resistance or suboptimal response to a prior TKI (phase I/II) - IT
Policlinico S. Orsola-Malpighi - Area S. Orsola
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

ITALY

LOMBARDIA
MONZA

Ongoing trial
A phase 1/2 study of SKI-606 in Philadelphia chromosome positive leukemias - IT
Azienda Ospedaliera San Gerardo
Unità di Ricerca Clinica

ITALY

LOMBARDIA
MONZA

Ongoing trial
Long term side effects of imatinib on Chronic Myeloid Leukemia (CLM) patients.
Azienda Ospedaliera San Gerardo
Unità di Ricerca Clinica

NETHERLANDS

Gelderland
NIJMEGEN

NETHERLANDS

Zuid-Holland
ROTTERDAM

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
Erasmus MC - Erasmus Medisch Centrum
Kankercentrum Daniel den Hoed

SPAIN

Aragón
ZARAGOZA

SPAIN

Cataluña
BARCELONA

SPAIN

Comunidad Valenciana
VALENCIA

Ongoing trial
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib - ES
IIS La Fe - Instituto de Investigación Sanitaria La Fe
Grupo de Investigación Clínica y Traslacional en Cáncer

SPAIN

Madrid
MADRID

UNITED KINGDOM

Nottinghamshire
NOTTINGHAM

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

UNITED KINGDOM

Greater Manchester
NOT YET IDENTIFIED - UK

Multinational clinical trial(s)